Results 181 to 190 of about 53,966 (218)

Evaluation of Pain in Intravitreal Bevacizumab Injections

Current Eye Research, 2012
To evaluate the correlation between pain associated with intravitreal bevacizumab injection and the location of the injection.The study included 218 eyes of 218 patients, who received an intravitreal bevacizumab injection at our institution. Pain was measured by the Visual Analog Scale (VAS). Additional parameters recorded included age, sex, indication
Elad Moisseiev
exaly   +3 more sources

Intravitreal Bevacizumab in a Patient With Neovascular Glaucoma

Ophthalmic Surgery, Lasers and Imaging Retina, 2006
Abstract. The utility of intravitreal bevacizumab injection in a patient with neovascular glaucoma following central retinal vein occlusion is explored. Bevacizumab (1 mg in 0.04 mL) was used after failed intraocular pressure (IOP) control with transscleral cyclophotocoagulation and panretinal photocoagulation.
Malik Y, Kahook, Joel S, Schuman, Robert J, Noecker   +2 more
openaire   +2 more sources

TESTING INTRAVITREAL TOXICITY OF BEVACIZUMAB (AVASTIN)

Retina, 2006
To evaluate the retinal toxicity of varying doses of bevacizumab when injected intravitreally in rabbits. Bevacizumab has been approved by the US Food and Drug Administration for the treatment of metastatic colorectal cancer.Twelve New Zealand albino rabbits were used for this study and divided into four groups.
Roberta P A, Manzano, Gholam A, Peyman, Palwasha, Khan, Muhamet, Kivilcim   +3 more
openaire   +2 more sources

Intravitreal Ranibizumab and Bevacizumab: A Review of Risk

Seminars in Ophthalmology, 2007
Ranibizumab (Lucentis), a recombinant monoclonal antibody, blocks all active forms of vascular endothelial growth factor A and was the first treatment for age-related macular degeneration shown to improve visual acuity in a substantial percentage of patients rather than slowing visual loss.
Rima M, Dafer, Michael, Schneck, Thomas R, Friberg, Walter M, Jay   +3 more
openaire   +2 more sources

Intravitreal Bevacizumab for Uveitic Choroidal Neovascularization

Ocular Immunology and Inflammation, 2009
To report 5 cases of inflammatory choroidal neovascularization (CNV) that were treated with intravitreal bevacizumab.Six eyes of 5 patients with uveitic CNV were treated with 2.5 mg/0.1 mL of intravitreal bevacizumab. Main outcome measures were the changes in BCVA and reduction in the size of the CNV.The mean follow-up time was 15.3 months.
Priyanka P, Doctor, Pooja, Bhat, Reema, Sayed, C Stephen, Foster   +3 more
openaire   +2 more sources

Intravitreal Bevacizumab for Myopic Choroidal Neovascularization

Ophthalmic Surgery, Lasers and Imaging Retina, 2008
Background and Objective: To evaluate the effect of intravitreal bevacizumab on visual acuity in patients with myopic choroidal neovascularization. Patients and Methods: The retrospective case series study included 13 patients with myopic choroidal neovascularization who received ...
Florian, Rensch, Ulrich H M, Spandau, Frank, Schlichtenbrede, Stefan, von Baltz, Teodosio, Libondi, Jost B, Jonas, Urs, Vossmerbaeumer   +6 more
openaire   +2 more sources

Intravitreal Injection of Bevacizumab in Eales Disease

Ocular Immunology and Inflammation, 2008
To report a case of presumed Eales disease that showed regression of retinal neovascularization after the use of intravitreal bevacizumab.Retrospective, interventional case report.Broad retinal neovascularization in a patient with presumed Eales disease did not regressed despite adequate photocoagulation treatment, and bevacizumab (1.25 mg) was ...
Cem, Küçükerdönmez, Yonca A, Akova, Gürsel, Yilmaz   +2 more
openaire   +2 more sources

Intravitreal injection of bevacizumab for retinopathy of prematurity

Japanese Journal of Ophthalmology, 2014
To evaluate the outcomes of intravitreal injection of bevacizumab (IVB) for retinopathy of prematurity (ROP).IVB was selected to be the first treatment for type 1 ROP in 8 eyes (4 patients). Bevacizumab (0.25 mg/eye) was injected into the vitreous cavity under either general anesthesia or sedation.
Kazuki, Kuniyoshi, Koji, Sugioka, Hiroyuki, Sakuramoto, Shunji, Kusaka, Norihisa, Wada, Yoshikazu, Shimomura   +5 more
openaire   +2 more sources

Role of Intravitreal Bevacizumab in Neovascular Glaucoma

Journal of Ocular Pharmacology and Therapeutics, 2007
We report on the effect of intravitreal bevacizumab (IVB) for the treatment of neovascular glaucoma (NVG). A retrospective chart review of 6 consecutive cases of NVG was performed. The follow-up period was 3-19 months (average, 9.7 months). All patients received 1.25 mg (0.05 cc) of IVB followed by panretinal photocoagulation (PRP) approximately 1 week
Moataz E, Gheith, Ghada A, Siam, Daniela S Monteiro, de Barros, Sunir J, Garg, Marlene R, Moster   +4 more
openaire   +2 more sources

Radiation maculopathy treated with intravitreal bevacizumab

Archivos de la Sociedad Española de Oftalmología (English Edition), 2017
A 47 year-old woman with a choroidal melanoma developed a macular oedema secondary to radiation therapy 75 months after brachytherapy plaque. The patient received 3 intravitreal Bevacizumab injections.The patient had a good response to bevacizumab treatment.
J L, Sánchez-Vicente, A, Muñoz-Morales, M P, Galván-Carrasco, A, Castilla-Lázpita, C, Vital-Berral, A, Alfaro-Juárez, T, Rueda-Rueda   +6 more
openaire   +2 more sources